An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 2, 2014, Pages 279-291

  Rosa, Gian Marco ^a   Ferrero, Simone ^a   Ghione, Paola ^a   Valbusa, Alberto ^a   Brunelli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Coronary artery disease; Heart failure; Ivabradine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE;

ARTICLE; CORONARY ARTERY DISEASE; HEART DEATH; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MEDLINE; NONHUMAN; PHARMACODYNAMICS; PROGNOSIS; RISK FACTOR; SYSTEMATIC REVIEW;

ANIMALS; BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 84892753699     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.876005     Document Type: Article

References (81)

1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93: 1137-46
2. Stewart S, Ekman I, Ekman T, et al. A Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes 2010;3: 573-80
3. Chen J, Hsieh A, Dharmarajan K, et al. National trends in heart failure hospitalization after acute myocardial infarction for medicare beneficiaries: 1998-2010. Circulation 2013;128: 2577-84
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14): 1787-847
5. Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11: 281-91
6. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005;26: 943-5
7. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353: 9-13
8. Thackray SDR, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006;152: 9-13
9. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357: 1385-90
10. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNI- CUS) study. Circulation 2002;106: 2194-9
11. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25: 1341-62
12. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651-8
13. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled- release metoprolol on total mortality, hospitalizations, and well- being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT- HF). MERIT-HF Study Group. JAMA 2000;283: 1295-302
14. Swedberg K. Pure heart rate reduction: further perspectives in heart failure. Eur Heart J Suppl 2007;9: 20-4
15. Mulder P, Barbier S, Chagroui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109: 1674-9
16. Thackray SDR, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006;713: 9-13
17. Gheorghiade M, Colucci WS, Swedberg K. Beta blockers in chronic heart failure. Circulation 2003;107: 1570-5
18. De Ferrari GM, Mazzuero A, Agnesina L. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008;10: 550-5
19. Savelieve I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31: 95-107
20. Dedkov E, Zheng W, Christensen L, et al. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagene. Am J Physiol Heart Circ Physiol 2007;293: 590-8
21. Robinson RB, Di Francesco D. Sinoatrial node and impulseinitiation. In: Spooner PM, Rosen MR, editors. Foundations of cardiac arrhythmias: basic concepts and clinical approaches. Marcel Dekker; New York; 2001. p. 151-70
22. DiFrancesco D. The cardiac hyperpolarizing-activated current If: origin and developments. Prog Biophys Mol Biol 1985;46: 163-83
23. Di Francesco D. The contribution of the "pace-maker" current (If) to generation of spontaneous activity in rabbit sinoatrial node myocytes. J Physiol 1988;405: 477-91
24. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118: 1051-7
25. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sinoatrial node If channels by ivabradine. J Gen Physiol 2002;120: 1-13
26. DiFrancesco D. If current inhibitors: properties of drug-channel interaction. In: Fox K, editor. Selective and specific if channel inhibition in cardiology. Science Press Ltd; London; 2004. p. 1-13
27. DiFrancesco D, Camm JA. heart rate lowering by specific and selective if current inhibition with ivabradine a new therapeutic perspective in cardiovascular disease. Drugs 2004;64: 1757-65
28. DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 1991;351: 145-7
29. DiFrancesco D, Ducouret P, Robinson RB. Muscarinic modulation of cardiac rate at low acetylcholine concentrations. Science 1989;243: 669-71
30. DiFrancesco D. The onset and autonomic regulation of cardiac pacemaker activity: relevance of the f current. Cardiovasc Res 1995;29: 449-56
31. DiFrancesco D. The pacemaker current If plays an important role in regulating SA node pacemaker activity. Cardiovasc Res 1995;30: 307-8
32. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D 2003;4: 83-9
33. Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic- pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998;64: 192-203
34. Portoles A, Calvo A, Terleira A, et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokineticinteraction clinical trial. J Clin Pharmacol 2006;46: 1195-203
35. Portoles A, Terleira A, Calvo A. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006;46: 1188-94
36. Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between ivabradine and phenyoinin healthy subjects. Clin Drug Investig 2012;32: 533-8
37. Vlase L, Neag M, Popa A, et al. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther 2011;36: 225-9
38. Choi HY, Noh YH, Cho SH, et al. Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5 or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers. Clin Ther 2013;35: 819-35
39. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26: 2529-36
40. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67: 393-405
41. Lopez-Bescos L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 2007;108: 387-96
42. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebocontrolled trial. Lancet 2008;372: 807-16
43. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372: 817-21
44. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30: 2337-45
45. Heusch G. A BEAUTIFUL lesson-ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J 2009;30: 2300-1
46. Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol 2008;155: 970-1
47. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008;118: 1915-19
48. Nerla R, Di Franco A, Milo M, et al. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart 2012;98: 1812-16
49. Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules 2012;17: 4924-35
50. Ceconi C, Freedman SB, Tardif JC, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 2011;146: 408-14
51. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376: 875-85
52. Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study. Eur Heart J 2012;33: 2813-20
53. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011;32: 2395-404
54. Ekman I, Cleland JG, Swedberg K, et al. Symptoms in patients with heart failure and prognostic predictors insights from COMET. J Cardiol Fail 2005;11: 288-99
55. Lesman-Leegte I, Jaazsma T, Coyne JC, et al. Quality of life and depressive symptoms in elderly: a comparison between patients with heart failure and age- and gender-matched community control. J Cardiac Fail 2009;15: 17-23
56. Zuluaga MC, Guailar-Castillon P, Lopez-Garcia F, et al. Generic and disease-specific quality of life is a predictor of long term mortality in heart failure. Eur J Heart Fail 2010;12: 1372-8
57. Dobre D, Van Jaarsveld CH, De Jongste MJ, et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-anaysis. Pharmacoepidemiol Drug Saf 2007;16: 152-9
58. Petterson KI, Reikvam A, Rollag A, et al. Reliability and validity of the KANSAS CITY cardiomyopathy questionnaire in patients with previous myocardial infarction. Eur J Heart Fail 2005;7: 235-42
59. Heidenreich PA, Spertus JA, Jones PG, et al. Health status identifies heat failure outpatients at risk for hospitalization or deat. J Am Coll Cardiol 2006;47: 752-6
60. Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with Ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011;32: 2507-15
61. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an International forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35: 569-82
62. Gupta RC, Wang M, Lisar I. Heart rate reduction with ivabradine improves sarcoplasmic reticulum cycling in left ventricular myocardium of dogs with moderate heart failure. J Am Coll Cardiol 2011;57:323
63. Go AS, Yang J, Gurwitz JH, et al. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tatrate, carvedilol) on the risk of rehospitalisation in adults with heart failure. Am J Cardiol 2007;100: 690-6
64. St John Sutton M, Ghio S, Plappert T, et al. Resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009;120: 1858-65
65. Liao L, Allen LA, Whellan DJ. Echonomic burden of heart failure in the elderly. Pharmacoeconomics 2008;26: 447-62
66. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009;119: 2516-25
67. Savelieva I, Camm AJ. I f inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008;31: 95-107
68. Tavazzi L, Swedberg K, Komajda M, et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 2013; In press
69. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993;73: 413-67
70. Muntwyler J, Cohen-Solal A, Freemantle N, et al. Relation of sex, age, and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004;6: 663-8
71. Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 2007;160: 383-90
72. Joannides R, Moore N, Iacob M. Comparative effects of ivabradine, a selective heart ratelowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2006;61: 127-37
73. Borer JS, Le Heuzey JY. Characterization of the heart rate lowering action of ivabradine, a selective If current inhibitor. Am J Ther 2008;15: 461-73
74. Babu KS, Gadzik F, Holgate ST. Absence of respiratory effects with ivabradine in patients with asthma. Br J Clin Pharmacol 2008;66: 96-101
75. Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes of patients with chronic heart failure and chronic obstructive pulmonary disease: efficacy and safety of ivabradine. A shift study analysis. Eur Heart J 2013;34:652
76. Komajda M, Bohm M, Borer J. Influence of background treatment with mineralcorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail 2013;15: 79-84
77. Ferrari R. A step further with ivabradine: signify (Study of assessING the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Eur Heart J 2009;11: 19-27
78. Gewirtz H. "Funny" current: If heart rate slowing is not the best answer, what might be? Cardiovasc Res 2009;84: 9-10
79. Deedwania P, Carbajal E, Dietz R, et al. Ivabradine in patients with coronary artery disease. Heart rate is a powerful predictor of mortality in post-AMI patients with heart failure: results from the Ephesus trial. Eur Heart J 2006;27:590
80. Fang Y, Debunne M, Vercauteren M, et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 2012;59: 260-7
81. Koncz I, Szel T, Bitay M, et al. Electrophysiological effects of ivabradine in dog and human cardiac preparations: Potential antiarrhythmic actions. Eur J Pharmacol 2011;668:419-26